Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Will Cymbalta, E Keppra Face Generic Competition This Year? Vesicare, Aloxi Too?
January 20, 2021
- Sanofi Files Pompe Therapy Avalglucosidase Alfa in Japan
January 20, 2021
- Shionogi Files Xofluza for Continuous Manufacturing in Japan
January 20, 2021
- Rep Promotions via Virtual, Face-to-Face Meetings Dip in November: Intage
January 20, 2021
- Takeda Alumni Setting Up Biz Circle for Ex- and Current Employees
January 19, 2021
- Health Damages Tied to Kobayashi Kako Mix-Up Increase to 214
January 19, 2021
- Xarelto Now Available in OD Tablets, Japan-Specific Dosage Form
January 19, 2021
- Enhertu Gets FDA Nod for Gastric Cancer, 2nd Indication in US
January 19, 2021
- Mitsubishi Tanabe, Takeda Share Experimental Data to Speed Up Drug Discovery
January 19, 2021
- BIKEN to Stop Shipment of Japanese Encephalitis Vaccine on Bacterial Contamination
January 18, 2021
- Vietnam’s Ha Tay Now an ASKA Group Company
January 18, 2021
- Janssen Files Imbruvica for Post-Transplant GVHD in Japan
January 18, 2021
- Taiho Sets Up Stand-Alone Subsidiary in Switzerland
January 18, 2021
- Chiome Licenses Anti-TROP-2 Antibodies to China Firm
January 18, 2021
- Zeria, Astellas Wind Up Copromotion for Acofide
January 18, 2021
- Only 1/338th the Number of Flu Patients in December 2020 vs December 2019: Survey
January 18, 2021
- Sawai Continues Shipment Control, Supply Suspensions for 5 Drugs on COVID-19, Recalls by Peers
January 18, 2021
- Towa, Nissin to Recall Dipyridamole Over PMD Law Violation by API Warehouse Operator
January 18, 2021
- Kolon Ordered Payment to Mitsubishi Tanabe over Cell Therapy License Deal
January 15, 2021
- Genmab Set for Stand-Alone Drug Development, Biz in Japan
January 15, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…